Pfizer, SFJ Pharma To Conduct Phase III Asian Trials Of Carcinoma Drug
This article was originally published in PharmAsia News
Executive Summary
U.S.-based SFJ Pharma is to conduct final-phase trials in Asia of Pfizer’s axitinib for renal cell carcinoma.